Arakawa Nobuyuki, Okubo Ayaka, Yasuhira Shinji, Takahashi Kazuhiro, Amano Hiroo, Akasaka Toshihide, Masuda Tomoyuki, Shibazaki Masahiko, Maesawa Chihaya
Department of Tumor Biology, Institute of Biomedical Science, Iwate Medical University, Iwate 028-8505, Japan.
Department of Dermatology, Iwate Medical University, Iwate 028-3694, Japan.
Oncol Lett. 2018 Feb;15(2):2393-2400. doi: 10.3892/ol.2017.7618. Epub 2017 Dec 14.
NAD(P)H quinone oxidoreductase 1 (NQO1)-dependent antitumor drugs such as β-lapachone (β-lap) are attractive candidates for cancer chemotherapy because several tumors exhibit higher expression of NQO1 than adjacent tissues. Although the association between NQO1 and β-lap has been elucidated, the effects of a NQO1-inducer and β-lap used in combination remain to be clarified. It has previously been reported that melanoma cell lines have detectable levels of NQO1 expression and are sensitive to NQO1-dependent drugs such as 17-allylamino-17-demethoxygeldanamycin. The present study was conducted to investigate the involvement of NQO1 in β-lap-mediated toxicity and the utility of combination treatment with a NQO1-inducer and β-lap in malignant melanoma cell lines. Decreased expression or inhibition of NQO1 caused these cell lines to become less sensitive to β-lap, indicating a requirement of NQO1 activity for β-lap-mediated toxicity. Of note was that carnosic acid (CA), a compound extracted from rosemary, was able to induce further expression of NQO1 through NF-E2 related factor 2 (NRF2) stabilization, thus significantly enhancing the cytotoxicity of β-lap in all of the melanoma cell lines tested. Taken together, the data presented in the current study indicated that the NRF2-NQO1 axis may have potential value as a therapeutic target in malignant melanoma to improve the rate of clinical response to NQO1-dependent antitumor drugs.
NAD(P)H醌氧化还原酶1(NQO1)依赖性抗肿瘤药物,如β-拉帕醌(β-lap),是癌症化疗中颇具吸引力的候选药物,因为一些肿瘤组织中NQO1的表达水平高于相邻组织。尽管NQO1与β-lap之间的关联已得到阐明,但NQO1诱导剂与β-lap联合使用的效果仍有待明确。此前有报道称,黑色素瘤细胞系可检测到NQO1表达水平,且对NQO1依赖性药物如17-烯丙基氨基-17-去甲氧基格尔德霉素敏感。本研究旨在探讨NQO1在β-lap介导的毒性中的作用,以及NQO1诱导剂与β-lap联合治疗在恶性黑色素瘤细胞系中的效用。NQO1表达降低或受到抑制会导致这些细胞系对β-lap的敏感性降低,这表明β-lap介导的毒性需要NQO1的活性。值得注意的是,从迷迭香中提取的化合物鼠尾草酸(CA)能够通过稳定NF-E2相关因子2(NRF2)来进一步诱导NQO1的表达,从而显著增强β-lap在所有测试黑色素瘤细胞系中的细胞毒性。综上所述,本研究提供的数据表明,NRF2-NQO1轴作为恶性黑色素瘤的治疗靶点,可能具有潜在价值,有助于提高对NQO1依赖性抗肿瘤药物的临床反应率。